case_images: PMC3726753_01
case_images: PMC3726753_02
case_images: PMC3726753_03
case_images: Morphoproteomics and Immunohistochemistry Patients #1, 2.. In patient #1 (DSRCT) the PI3K/Akt/mammalian target of rapamycin (mTOR) pathway is constitutively activated by p-Akt (Ser 473) expression in the nuclear compartment of the tumor cells and p-mTOR phosphorylated on Ser 2448, suggesting mTORC2 (rictor+mTOR) as the dominant form. In patient #2 (Wilm's tumor), the mTOR pathway is also activated with most tumor cells moderately expressing p-mTOR (Ser 2448) in plasmalemmal and cytoplasmic compartments. This coincides with the constitutive activation of one of the downstream effectors of the mTORC1 signaling pathway, namely p-p70S6K (Thr 389). There is constitutive activation of the Ras/Raf kinase/extracellular signal-regulated kinase (ERK) pathway p-ERK 1/2 (Thr202/Tyr204) expression in the Wilms tumor.
case_images: pone.0068985.g001.jpg
case_images: PMC3726753_03_pone.0068985.g001.jpg
case_images: pone-0068985-g001
case_images: Notably, a minor but significant portion of the tumor nuclei express p-signal transducer and activator of the transcription (STAT) 3 (Tyr 705) in their nuclei in some regions (Figure 1).